Article(id=1304388238093873660, tenantId=1146029695717560320, journalId=1302319053441957962, issueId=1304388157621948709, articleNumber=null, orderNo=null, doi=10.7501/j.issn.0253-2670.2026.15.034, pmid=null, cstr=null, oa=null, hot=0, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1772294400000, receivedDateStr=2026-03-01, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1788919990322, onlineDateStr=2026-09-09, pubDate=null, pubDateStr=null, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1788919990322, onlineIssueDateStr=2026-09-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1788919990322, creator=13701087609, updateTime=1788919990322, updator=13701087609, issue=Issue{id=1304388157621948709, tenantId=1146029695717560320, journalId=1302319053441957962, year='2026', volume='57', issue='15', pageStart='5789', pageEnd='6208', issueExtLink='null', onlineDate='null', pubDate='1786464000000', pubDateStr='2026-08-12', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=1, specialIssue=null, createTime=1788919971137, creator='13701087609', updateTime=1788923514106, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1304403017982300207, tenantId=1146029695717560320, journalId=1302319053441957962, issueId=1304388157621948709, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1304403017982300208, tenantId=1146029695717560320, journalId=1302319053441957962, issueId=1304388157621948709, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=6201, endPage=6208, ext={EN=ArticleExt(id=1304388238425223679, articleId=1304388238093873660, tenantId=1146029695717560320, journalId=1302319053441957962, language=EN, title=Reflections on institutional logic and implementation pathways based on “Special Provisions for the Supervision and Administration of Traditional Chinese Medicine Production”, columnId=null, journalTitle=Chinese Traditional and Herbal Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=The “Special Provisions for the Supervision and Administration of Traditional Chinese Medicine Production” is China’s first regulatory document specifically designed to systematically regulate the oversight of traditional Chinese medicine (TCM) production. It signifies a deepening shift from general requirements to a specialized system that reflects the unique characteristics of TCM manufacturing. This development helps to enhance the standardization of TCM production and the stability of its quality, modernize regulatory approaches, and provide institutional support for building a drug regulation system tailored to TCM’s features, thereby promoting the high-quality development of the TCM industry. Grounded in the inherent characteristics of TCM-such as the natural origin of its raw materials, long quality formation chains, and complex influencing factors-the provisions establish a regulatory framework covering the entire TCM production lifecycle. This framework addresses key areas including source control of Chinese medicinal materials, production process management, testing and release, traceability systems, pharmacovigilance, and regulatory oversight. The institutional design emphasizes adherence to TCM principles, strengthens the subject responsibility of the marketing authorization holder, highlights source control, rigorous process management, and risk-based classification supervision. Furthermore, it provides detailed requirements for critical issues such as raw material homogenization, extract yield management, contract manufacturing, production resumption, and the oversight of TCM injections. By analyzing the background of its issuance, institutional logic, main content, key innovations, and implementation pathways, this paper aims to facilitate a deeper understanding of the significance of implementing these Special Provisions among the industry., authors=ZHANG Tideng, WAN Shun, YANG Diya, GUO Ying, LIU Chun, WANG Hainan, authorsList=ZHANG Tideng, WAN Shun, YANG Diya, GUO Ying, LIU Chun, WANG Hainan, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1304388238349726206, articleId=1304388238093873660, tenantId=1146029695717560320, journalId=1302319053441957962, language=CN, title=《中药生产监督管理专门规定》的制度逻辑与实施路径思考, columnId=1304388238282617341, journalTitle=中草药, columnName=药事管理, runingTitle=null, highlight=null, articleAbstract=《中药生产监督管理专门规定》是我国首部系统规范中药生产监管的专门规范性文件，标志着中药生产监管由通用要求向体现中药生产特点的专门制度进一步深化，有助于提升中药生产规范化水平和质量稳定性，推动监管方式现代化，为构建符合中药特点的药品监管体系、促进中药产业高质量发展提供制度支撑。该规定立足中药原料天然属性强、质量形成链条长、影响因素复杂等特点，围绕中药材源头控制、生产过程管理、检验放行、追溯体系、药物警戒和监督管理等关键环节，构建了覆盖中药生产全过程的监管框架。其制度设计突出遵循中药规律，强化药品上市许可持有人主体责任，强调源头治理、过程严控和风险分级监管，并对原料均一化处理、提取收率管理、委托生产、恢复生产和中药注射剂监管等重点问题作出具体要求。通过对出台背景、制度逻辑、主要内容、关键创新及实施路径等方面进行分析，助力业界对该规定实施的意义有更深刻的理解。, authors=张体灯1 , 万顺2 , 杨迪雅3 , 郭颖3 , 刘春3 , 王海南3 , authorsList=张体灯, 万顺, 杨迪雅, 郭颖, 刘春, 王海南, authorCompany=1 国家药品监督管理局高级研修学院, 北京 100073;
中草药
|药事管理
2026
, 57
(15) :
6201
-6208
《中药生产监督管理专门规定》的制度逻辑与实施路径思考
全屏
张体灯1 , 万顺2 , 杨迪雅3 , 郭颖3 , 刘春3 , 王海南3
作者信息
1 国家药品监督管理局高级研修学院, 北京 100073;
通讯作者:
刘春
作者简介:
张体灯: 张体灯，从事药品监管政策和监管科学研究。E-mail:ztd@nmpaied.org.cn
Reflections on institutional logic and implementation pathways based on “Special Provisions for the Supervision and Administration of Traditional Chinese Medicine Production”
ZHANG Tideng, WAN Shun, YANG Diya, GUO Ying, LIU Chun, WANG Hainan
Affiliations
doi: 10.7501/j.issn.0253-2670.2026.15.034
文章导航
《中药生产监督管理专门规定》是我国首部系统规范中药生产监管的专门规范性文件，标志着中药生产监管由通用要求向体现中药生产特点的专门制度进一步深化，有助于提升中药生产规范化水平和质量稳定性，推动监管方式现代化，为构建符合中药特点的药品监管体系、促进中药产业高质量发展提供制度支撑。该规定立足中药原料天然属性强、质量形成链条长、影响因素复杂等特点，围绕中药材源头控制、生产过程管理、检验放行、追溯体系、药物警戒和监督管理等关键环节，构建了覆盖中药生产全过程的监管框架。其制度设计突出遵循中药规律，强化药品上市许可持有人主体责任，强调源头治理、过程严控和风险分级监管，并对原料均一化处理、提取收率管理、委托生产、恢复生产和中药注射剂监管等重点问题作出具体要求。通过对出台背景、制度逻辑、主要内容、关键创新及实施路径等方面进行分析，助力业界对该规定实施的意义有更深刻的理解。
中药生产
/
监督管理
/
中药监管科学
/
全生命周期
/
分类监管
/
主体责任
/
质量控制
The “Special Provisions for the Supervision and Administration of Traditional Chinese Medicine Production” is China’s first regulatory document specifically designed to systematically regulate the oversight of traditional Chinese medicine (TCM) production. It signifies a deepening shift from general requirements to a specialized system that reflects the unique characteristics of TCM manufacturing. This development helps to enhance the standardization of TCM production and the stability of its quality, modernize regulatory approaches, and provide institutional support for building a drug regulation system tailored to TCM’s features, thereby promoting the high-quality development of the TCM industry. Grounded in the inherent characteristics of TCM-such as the natural origin of its raw materials, long quality formation chains, and complex influencing factors-the provisions establish a regulatory framework covering the entire TCM production lifecycle. This framework addresses key areas including source control of Chinese medicinal materials, production process management, testing and release, traceability systems, pharmacovigilance, and regulatory oversight. The institutional design emphasizes adherence to TCM principles, strengthens the subject responsibility of the marketing authorization holder, highlights source control, rigorous process management, and risk-based classification supervision. Furthermore, it provides detailed requirements for critical issues such as raw material homogenization, extract yield management, contract manufacturing, production resumption, and the oversight of TCM injections. By analyzing the background of its issuance, institutional logic, main content, key innovations, and implementation pathways, this paper aims to facilitate a deeper understanding of the significance of implementing these Special Provisions among the industry.
traditional Chinese medicine production
/
supervision and administration
/
regulatory science of traditional Chinese medicine
/
entire lifecycle
/
classified supervision
/
subject responsibility
/
quality control
张体灯, 万顺, 杨迪雅, 郭颖, 刘春, 王海南.
《中药生产监督管理专门规定》的制度逻辑与实施路径思考.
中草药,
2026
, 57
(15)
: 6201
-6208
.
DOI: 10.7501/j.issn.0253-2670.2026.15.034
ZHANG Tideng, WAN Shun, YANG Diya, GUO Ying, LIU Chun, WANG Hainan.
Reflections on institutional logic and implementation pathways based on “Special Provisions for the Supervision and Administration of Traditional Chinese Medicine Production”[J].
Chinese Traditional and Herbal Drugs ,
2026
, 57
(15)
: 6201
-6208
.
DOI: 10.7501/j.issn.0253-2670.2026.15.034
参考文献
引证文献
中共中央国务院关于促进中医药传承创新发展的意见[J]. 中华人民共和国国务院公报, 2019(31): 6-10.
2026年第57卷第15期
PDF下载
34
12
引用本文
BibTeX
文章信息
doi: 10.7501/j.issn.0253-2670.2026.15.034
接收时间：2026-03-01
首发时间：2026-09-09
https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.15.034
引用本文
BibTeX
2种不同金属材料的力学参数
科 属数 种数 占总种数比例 属 种数 占总种数比例 鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78 小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39 多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39 红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87 小菇属 Mycena 11 5.26 光柄菇属 Pluteus 5 2.39 红菇属 Russula 17 8.13 栓菌属 Trametes 5 2.39
关闭全屏
BibTeX
EndNote
RefWorks
TxT
PDF下载
全屏
34
12
关闭全屏
北京市海淀区学院南路86号
010-62199257（仅加盟咨询）
qkjq@cast.org.cn
